Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: Defined specificities may be associated with distinct clinical features

American Journal of Medicine

Volumn 105, Issue 5, 1998, Pages 393-399

  Roozendaal, Caroline ^a   Van Milligen De Wit, A W Marc ^b,d   Haagsma, Els B ^a   Horst, Gerda ^a   Schwarze, Carolynne ^c   Peter, Hans H ^c   Kleibeuker, Jan H ^a,c   Cohen Tervaert, Jan W ^a   Limburg, Pieter C ^a   Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF FREIBURG   (Germany)

^d Red Cross Hospital Den Haag   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; AGED; ANALYTIC METHOD; ANTIBODY DETECTION; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; BLOOD SAMPLING; CLINICAL FEATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; TARGET CELL;

ADULT; AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CHOLANGITIS, SCLEROSING; EPITOPES; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 0032211428     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00294-0     Document Type: Article

References (51)

1. 1. Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology. 1989;4:430-436.
2. 2. Farrant JM, Hayllar KM, Wilkinson ML, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology. 1991;100:1710-1717.
3. 3. Schrumpf E, Fausa O, Forre O, et al. HLA antigens and immuno-regulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol. 1982;17:187-191.
4. 4. Mehal WZ, Lo YM, Wordsworth BP, et al. HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis. Gastroenterology. 1994;106:160-167.
5. 5. Van Milligen de Wit AWM, Van Deventer SJH, Tytgat GNJ. Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies. Am J Gastroenterol. 1995;90:893-900.
6. 6. Chapman RW, Cottone M, Selby WS, et al. Serum autoantibodies, ulcerative colitis, and primary sclerosing cholangitis. Gut. 1986;27: 86-91.
7. 7. Whiteside TL, Lasky S, Si L, Van Thiel DH. Immunologic analysis of mononuclear cells in liver tissues and blood of patients with primary sclerosing cholangitis. Hepatology. 1985;5:468-474.
8. 8. Chapman RW, Kelly P, Heryet A, et al. Expression of HLA-DR antigens on bile duct epithelium in primary sclerosing cholangitis. Gut. 1988;29:422-427.
9. 9. Duerr RH, Targan SR, Landers CJ, et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 1991;100:1385-1391.
10. 10. Klein R, Eisenburg J, Weber P, et al. Significance and specificity of antibodies to neutrophils detected by western blotting for the serological diagnosis of primary sclerosing cholangitis. Hepatology. 1991;14:1147-1152.
11. 11. Mulder AHL, Horst G, Haagsma EB, et al. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology. 1993;17:411-417.
12. 12. Gur H, Shen G, Sutjita M, et al. Autoantibody profile of primary sclerosing cholangitis. Pathobiology. 1995;63:76-82.
13. 13. Bansi DS, Chapman RW, Fleming KA. Antineutrophil cytoplasmic antibodies in chronic liver diseases: prevalence, titre, specificity and IgG subclass. J Hepatol. 1996;24:581-586.
14. 14. Saxon A, Shanahan F, Landers CJ, et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990;86:202-210.
15. 15. Rump JA, Schölmerich J, Gross V, et al. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology. 1990;181: 406-413.
16. 16. Shanahan F. Neutrophil autoantibodies in inflammatory bowel disease: are they important? Gastroenterology. 1994;107:586-589.
17. 17. Seibold F, Schlametschka D, Gregor M, Weber P. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 1994;107:532-536.
18. 18. Kallenberg CGM, Mulder AHL, Cohen Tervaert JW. Antineutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders. Am J Med. 1992;93:675-682.
19. 19. Kallenberg CGM, Brouwer E, Weening JJ, Cohen Tervaert JW. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int. 1994;46:1-15.
20. 20. Lesavre P, Nusbaum P, Halbwachs-Mecarelli L. Methods of detection of anti-cathepsin G autoantibodies in human. Adv Exp Med Biol. 1993;336:257-261.
21. 21. Peen E, Almer S, Bodemar G, et al. Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease. Gut. 1993;34:56-62.
22. 22. Stoffel MP, Csernok E, Herzberg C, et al. Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders. Clin Exp Immunol. 1996;104:54-59.
23. 23. Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology. 1980;79: 200-206.
24. 24. O'Morain C, Tobin A, Leen E, et al. Criteria of case definition in Crohn's disease and ulcerative colitis. Scand J Gastroenterol. 1989; 24:7-11.
25. 25. Van der Woude FJ, Lobatto S, Permin H, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985;i:425-429.
26. 26. Wiik A. Delineation of a standard procedure for indirect immuno-fluorescence detection of ANCA. APMIS. 1989;97(suppl 6):12-13.
27. 27. Van der Giessen M, Huitema MG, Cohen Tervaert JW, Kallenberg CGM. A technical note on the routinely performed ANCA detection. APMIS. 1989;97(suppl 6):37.
28. 28. Goldschmeding R, Van der Schoot CE, Ten Bokkel Huinink D, et al. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest. 1989;84:1577-1587.
29. 29. Cohen Tervaert JW, Goldschmeding R, Elema JD, et al. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int. 1990;37:795-806.
30. 30. Zhao MH, Jones SJ, Lockwood CM. Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol. 1995;99:49-56.
31. 31. Lo SK, Fleming KA, Chapman RW. Prevalence of anti-neutrophil antibody in primary sclerosing cholangitis and ulcerative colitis using an alkaline phosphatase technique. Gut. 1992;33:1370-375.
32. 32. Falk RJ, Jennette JC. Antineutrophil cytoplasmic antibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic and crescentic glomerulonephritis. NEJM. 1988; 318:1651-1657.
33. 33. Halbwachs-Mecarelli L, Nusbaum P, Noel LH, et al. Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis. Clin Exp Immunol. 1992;90:79-84.
34. 34. Kallenberg CGM, Cohen Tervaert JW, Limburg PC. ELISA for the detection of antibodies against neutrophil cytoplasm antigens. Team Diagnost Pathol. 1991;2:43-60.
35. 35. Coremans IEM, Hagen EC, Daha MR, et al. Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis. Arthritis Rheum. 1992;35:1466-1475.
36. 36. Jones SJ, Zhao MH, Elliott JD, Lockwood CM. The antigenicity of bactericidal/permeability-increasing protein (BPI) is threatened by serine proteinases. Clin Exp Immunol. 1995;101(suppl 1):36. Abstract.
37. 37. Pokorny CS, Norton ID, McCaughan GW, Selby WS. Anti-neutrophil cytoplasmic antibody: a prognostic indicator in primary sclerosing cholangitis. J Gastroenterol Hepatol. 1994;9:40-44.
38. 38. Roozendaal C, Zhao MH, Horst G, et al. Catalase and alphaenolase: two novel granulocyte autoanigens in inflammatory bowel diseases. Clin Exp Immunol. 1998;112:10-16.
39. 39. Mulder AHL, Broekroelofs J, Horst G, et al. Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates. Clin Exp Immunol. 1994;95: 490-497.
40. 40. Hardarson S, Labrecque DR, Mitros FA, et al. Antineutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary diseases. High prevalence in ulcerative colitis, primary sclerosing cholangitis, and autoimmune hepatitis. Am J Clin Pathol. 1993;99: 277-281.
41. 41. Bansi DS, Fleming KA, Chapman RW. Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass. Gut. 1996;38: 384-389.
42. 42. Kallenberg CGM, Brouwer E, Mulder AHL, et al. ANCA: pathophysiology revisited. Clin Exp Immunol. 1995;100:1-3.
43. 43. Zhao MH, Jayne DRW, Ardiles L, et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI) in cystic fibrosis. Q J Med. 1996;89:259-265.
44. 44. Mulder AHL, Horst G, Van Leeuwen MA, et al. Anti-neutrophil cytoplasmic antibodies in rheumatoid arthritis: characterization and clinical correlates. Arthritis Rheum. 1993;36:1054-1060.
45. 45. Nässberger L, Hultquist R, Sturfelt G. Occurrence of anti-lactoferrin antibodies in patients with systemic lupus erythematosus, hydralazine-induced lupus, and rheumatoid arthritis. Scand J Rheumatol. 1994;23:206-210.
46. 46. Schnabel A, Csernok E, Isenberg DA, et al. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Prevalence, specificities, and clinical significance. Arthritis Rheum. 1995;38:633-637.
47. 47. Elsbach P, Weiss J. The bactericidal/permeability-increasing (BPI), a potent element in host-defense against Gram-negative bacteria and LPS. Immunobiology. 1993;87:417-429.
48. 48. Dunn AC, Zhao MH, Lockwood CM. Rabbit polyclonal antibodies to bactericidal/permeability-increasing protein (BPI) inhibit LPS induced endothelial cell injury. Sarcoidosis. 1996;13:259. Abstract.
49. 49. Falk RJ, Terrell RS, Charles LA, Jennette C. Anti-neutrophil cytoplasmic antibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA. 1990;87:4115-4119.
50. 50. Mulder AHL, Heeringa P, Brouwer E, et al. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies: a FcγRII-dependent process. Clin Exp Immunol. 1994;98:270-278.
51. 51. Peen E, Sundqvist T, Skogh T. Leukocyte activation by anti-lactoferrin antibodies bound to vascular endothelium. Clin Exp Immunol. 1996;103:403-407.